A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs RA 101495 (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 According to a Ra Pharmaceuticals media release, the company anticipates dosing the first patient in the fourth quarter of 2017.
    • 18 Oct 2017 Status changed from planning to recruiting.
    • 05 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top